RTL 1000

Drug Profile

RTL 1000

Alternative Names: RTL1000; VG1000

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Oregon Health & Science University
  • Developer Artielle ImmunoTherapeutics
  • Class
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 18 May 2016 Phase I development is ongoing in USA
  • 19 Apr 2010 Final adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in relapsing-remitting multiple sclerosis presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN-2010)
  • 14 Sep 2009 Efficacy and Adverse Event data from a phase I trial in Multiple sclerosis presented at the 13th Congress of the European Federation of Neurological Societies(EFNS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top